Literature DB >> 31010564

Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.

Hendrée E Jones1, Walter K Kraft2.   

Abstract

When opioid misuse rises in the United States, pregnant women and their neonates are affected. This article summarizes the use of Food and Drug Administration-approved products, including methadone, buprenorphine, and the combination formulation of buprenorphine and naloxone to treat adult opioid use disorder during the perinatal period. All labels include pregnancy, neonatal, and lactation information and note the accepted use of these medications during the perinatal period if the benefits outweigh the risks. A summary of the neonatal abstinence syndrome definition, its assessment tools, treatment approaches, and future genetic directions are provided.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Addiction; NAS; NOWS; Neonatal; Neonatal abstinence syndrome; Neonatal opioid withdrawal; Opioid use disorder; Prenatal

Year:  2019        PMID: 31010564     DOI: 10.1016/j.clp.2019.02.013

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  7 in total

Review 1.  Optimal Care for NAS: Are We Moving in the Wrong Direction?

Authors:  Lauren M Jansson; Martha L Velez
Journal:  Hosp Pediatr       Date:  2019-08

Review 2.  Opioid Use in Pregnancy.

Authors:  Amalia Londono Tobon; Erin Habecker; Ariadna Forray
Journal:  Curr Psychiatry Rep       Date:  2019-11-16       Impact factor: 5.285

3.  Licit and illicit drug use across trimesters in pregnant women endorsing past-year substance use: Results from National Survey on Drug Use and Health (2009-2019).

Authors:  MacKenzie R Peltier; Walter Roberts; Terril L Verplaetse; Catherine Burke; Yasmin Zakiniaeiz; Kelly Moore; Sherry A McKee
Journal:  Arch Womens Ment Health       Date:  2022-06-23       Impact factor: 4.405

Review 4.  Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.

Authors:  Lori A Devlin; Leslie W Young; Walter K Kraft; Elisha M Wachman; Adam Czynski; Stephanie L Merhar; T Winhusen; Hendrée E Jones; Brenda B Poindexter; Lauren S Wakschlag; Amy L Salisbury; Abigail G Matthews; Jonathan M Davis
Journal:  J Perinatol       Date:  2021-09-23       Impact factor: 3.225

5.  Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.

Authors:  Daniel Saal; Frank Lee
Journal:  Perm J       Date:  2020-03-13

6.  Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.

Authors:  Brooks T McPhail; Chie Emoto; Tsuyoshi Fukuda; Dawn Butler; Jason R Wiles; Henry Akinbi; Alexander A Vinks
Journal:  J Clin Pharmacol       Date:  2019-12-09       Impact factor: 3.126

7.  Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome.

Authors:  Rena Eudy-Byrne; Nicole Zane; Susan C Adeniyi-Jones; Marc R Gastonguay; Ana Ruiz-Garcia; Gagan Kaushal; Walter K Kraft
Journal:  Clin Transl Sci       Date:  2021-09-16       Impact factor: 4.438

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.